Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.63 |
| ▸ | RAB9A | P51151 | 8/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 7/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371515 | 0.85 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2MAPTTSHR | |
| SCHEMBL12371511 | 0.81 | CHRNB2 (0.66) | NPC1RAB9ASMN1; SMN2MAPTTSHR | |
| SCHEMBL66168 | 0.81 | RAB9A (0.71) | NPC1RAB9ASMN1; SMN2MAPTCASP3 | |
| SCHEMBL60681 | 0.78 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2MAPTCASP3 | |
| SCHEMBL18292540 | 0.78 | MAPT (0.63) | NPC1RAB9ASMN1; SMN2MAPTCASP3 | |
| SCHEMBL1423475 | 0.78 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2MAPTCASP3 | |
| SCHEMBL18292543 | 0.77 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2MAPTCASP3 | |
| SCHEMBL1422469 | 0.75 | CHRNB2 (0.74) | NPC1RAB9ASMN1; SMN2MAPTTSHR | |
| SCHEMBL1423975 | 0.75 | CHRNB2 (0.74) | NPC1RAB9ASMN1; SMN2MAPTTSHR | |
| SCHEMBL2273610 | 0.72 | CHRNB2 (0.67) | NPC1RAB9ASMN1; SMN2MAPTCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-9186407-B2 | Pharmaceutical compositions and their methods of use | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9040568-B2 | Pharmaceutical compositions for the treatment of pain | ABBVIE INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8486979-B2 | Analgesics; central nervous system disorders; attentiondeficit disorders;cognition activators; bipolar disorders; Alzheimer's disease; Down's syndrome; brain disorders | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110190314-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
| US-20100305086-A1 | Pharmaceutical Compositions for the Treatment of Pain | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190314-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | CHRNA4, CHRNB4, CHRNA5 | NPC1 1677/4885RAB9A 1978/4885SMN1; SMN2 479/4885 |
| US-20100305086-A1 | Pharmaceutical Compositions for the Treatment of Pain | CHRNA1, CHRNG, CHRNA4 | NPC1 2912/4885RAB9A 2342/4885SMN1; SMN2 1623/4885 |
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | OXA1L, CYP11B2, CYP1B1 | NPC1 1201/4885RAB9A 4444/4885SMN1; SMN2 2521/4885 |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | CHRNA4, CHRNB4, CHRNA5 | NPC1 1677/4885RAB9A 1978/4885SMN1; SMN2 479/4885 |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | CHRNA4, CHRNB4, CHRNA5 | NPC1 1677/4885RAB9A 1978/4885SMN1; SMN2 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.